Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As used in this Current Report on Form 8-K, and unless otherwise indicated, the terms “the Registrant”, “the Company,” “Organicell,” “we,” “us” and “our” refer to Organicell Regenerative Medicine, Inc.
Item 8.01 Other Events.
On August 20, 2020, Organicell issued a press release in which it announced that the U.S. Food and Drug Administration (FDA) granted emergency, expanded access approval to treat one “long-hauler” patient on August 1, 2020, and two additional patient approvals on August 17, 2020.
A copy of the Company’s press release dated August 20, 2020 is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
First Reported “Long-Hauler” Post COVID-19 Patient Treated with Zofin™ Produces Excellent Preliminary Results
MIAMI--(BUSINESS WIRE)-- Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted emergency, expanded access approval to treat one “long-hauler” patient on August 1, 2020, and two additional patient approvals on August 17, 2020.
In the first approval, prior to treatment with Zofin, the patient was hospitalized for seven weeks. At the time of discharge, the patient was physically limited due to severe deconditioning and having shortness of breath while performing limited activities of daily living (eating meals, showering and short distance walking). After receiving three doses of Zofin, he is now free of post-COVID-19 complications and plans to return to work on September 1, 2020.
Organicell is the first reported company to treat outpatient COVID-19 long-haulers. In a July 24, 2020 report, the U.S. Centers for Disease Control and Prevention (CDC), found that of about 300 non-hospitalized but symptomatic COVID-19 patients, 35% were still experiencing symptoms like coughing, shortness of breath and fatigue up to three weeks after diagnosis. (By contrast, less than 10% of non-hospitalized influenza patients are not fully recovered within two weeks.) Recovery from COVID-19 can be a drawn-out process for patients of all ages, genders and prior levels of health, “potentially leading to prolonged absence from work, studies, or other activities,” the report noted.1
George Shapiro, M.D., Chief Medical Officer of Organicell said, “Organicell believes that ‘long-haulers” are a population of COVID-19 patients that need immediate help to return to normalcy, and as per Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Disease recently noted, it will take months to a year or more to know whether lingering COVID-19 symptoms in young people could become chronic illnesses2.”
Recently, Organicell broadened its focus to treat mild to moderate COVID-19 patients, as well as those patients that are more severely affected. Previously, three severely ill COVID-19 patients were treated with Zofrin at Landmark Hospital in Athens, GA, and two mild to moderate acute respiratory syndrome (SARS) patients were treated under an emergency investigational new drug expanded access program, with all patients reporting excellent results.
“Organicell believes that there is hope for the thousands of people suffering with post-COVID symptoms that can’t return to work, school or their daily lives. These long-haulers will not be forgotten,” said Albert Mitrani, Chief Executive Officer of Organicell.
Organicell is preparing to submit additional phase I/II INDs to treat COVID-19 long-haulers.
About Organicell Regenerative Medicine, Inc.:
Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company that harnesses the power of nanoparticles to develop innovative biological therapeutics for the treatment of degenerative diseases. The company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Maria Ines Mitrani, Chief Science Officer. To learn more, please visit https://organicell.com/.
Nah, it has to be verified before I spout it off, I can wait, not looking to flip, all my holdings are on a 1 year timeline
OK, Jungle drums have started beating, it's only a rumor from a third party and not verifiable, possibly this could be a start, we shall see.
It is a very complicated process, ALL shares have to be accounted for and delivered, the transfer agent and the accountant have to be in agreement. It becomes a major paper shuffle, it's not like going out to buy a loaf of brd.
The Company is pleased to call attention to its recently filed second quarter results. The report shows a dramatic revenue increase over the first quarter. This occurred in the company's largest revenue generating subsidiary, Tieshan Oil.
During the first quarter results for TO were down drastically due to lack of gasoline sales in China. The first quarter lack of sales was directly caused by worldwide conditions. Second quarter results show a 400+% increase in revenue over the first quarter. This increase is attributed to higher demand for gasoline in China as fears diminished. Revenue has not reached the levels of 2019 in the second quarter but sales are showing a trend towards recovery.
CEO DS Chang commented "We are happy to see our core division returning to fiscal health. We hope illness does not revisit a damper on demand for fuel in China and that Tieshan Oil will continue to flourish and grow".
Furthermore, the Company is conducting ongoing due diligence on potential acquisitions of revenue generating, profitable enterprises.
In the instance of a certain infectious control company border closings and travel limitations have slowed the process by preventing onsite inspections from Company teams. Even so, other parts of the process continue forward.
The Wandi Mining acquisition has yet to close. The Company has tendered its share consideration to Wandi. However, Wandi has yet to deliver its shares to the Company as required to close the transaction. The Wandi shares are shown as "Subscription receivable for acquisition of Wandi" in the financial statements in our latest quarterly report. We anticipate that the Wandi transaction will close prior to the end of 2020.
For information on Phoenix Rising Companies visit www.phoenix-cos.com
contact ir@phoenix-cos.com
CAUTIONARY STATEMENT
This press release contains forward-looking statements. Known and unknown risks may cause actual future results to vary widely. The statements are based upon Management's and Advisor's current expectations, estimates and projections; are not guarantees of future performance and are subject to certain risks and uncertainties and other factors, some of which are beyond Management's control and are difficult to predict. A reader of this press release should not place undue reliance on forward-looking statements. Investors should understand investing in shares of RSSV involves a high degree of risk and should seek competent investment advice prior to purchasing shares.
SOURCE: Phoenix Rising Companies
Item 8.01 Other Events.
On August 20, 2020, Organicell issued a press release in which it announced that the U.S. Food and Drug Administration (FDA) granted emergency, expanded access approval to treat one “long-hauler” patient on August 1, 2020, and two additional patient approvals on August 17, 2020.
A copy of the Company’s press release dated August 20, 2020 is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
If they are successful through all their trials and move to production we are all going to change our zip code.
The reality is it has to work, i will give them a year to figure it out and will not worry bout price tag, I follow story lines.
When you have the Science Officer and former directors taking stock positions in a company do you have to ask yourself why???
IN!, initial position, could be explosive and well worth the wait.
As usual this will be a 1 year buy and hold.
The Depository Trust Company (DTC), established in 1973, was created to reduce costs and provide clearing and settlement efficiencies by immobilizing securities and making "book-entry" changes to ownership of the securities.
DTC brings efficiency to the securities industry by retaining custody of more than 1.3 million active securities issues valued at US$54.2 trillion as of 7/31/2017, including securities issued in the US and more than 131 countries and territories.
DTC provides securities movements for NSCC's net settlements, and settlement for institutional trades (which typically involve money and securities transfers between custodian banks and broker/dealers), as well as money market instruments.
DTC's core services include:
Settlement Services
Corporate Actions Processing
Securities Processing
Issuer Services
Underwriting Services
Global Tax Services
DTCC's Settlement Services, offered through DTC, reduce cost and risk and boost efficiencies in the marketplace by providing end-of-day net settlement obligations for clients resulting from trading activity in equities, debt and money market instruments. Asset Servicing, also offered through DTC, offers a broad range of services for underwriting, custody, corporate actions, dividend, proxy and reorganization services, as well as the electronic registration and transfer of securities.
DTC is a member of the U.S. Federal Reserve System, a limited-purpose trust company under New York State banking law and a registered clearing agency with the U.S. Securities and Exchange Commission.
Held at DTC
49,007,676 verified correct 07/31/2020
Tomorrow I could care less about.
My buy and holds are 1 year minimum, not all penny players are playing with pennies.
If the B.S. gets too deep around here, I just shut off the noise, too many lost portfolios with an internet habit around here.
Sorry but that aint gonna happen
IQST Security Details
Share Structure
Market Cap Market Cap
4,855,796
08/17/2020
Authorized Shares
300,000,000
07/31/2020
Outstanding Shares
72,598,774
07/31/2020
Restricted
23,443,319
07/31/2020
Unrestricted
49,155,455
07/31/2020
Held at DTC
49,007,676
07/31/2020
Float
21,608,812
03/31/2020
this share structure is golden as it is.
Hey!! Outside world!! The July revenues is the same as the market cap for the entire company.........
iQSTEL Starts Off Q3 With $4.3M in July Revenues, a 290% Increase Over 2019, Expects to Surpass 2020 Q2 Revenues of $11.1M
Loading this boat to the gunnels.
It's all about market cap and float. Never I mean Never have I seen old shareholders have enough votes to control a board of a new company they are not a part of. Good lord
I grabbed some PUPS today, should be an outstanding R/M play with a very small float and the market cap is only 1 milly.
As with all my holdings they have a one year exploration date.. I just trade differently than most, but man does it ever work.
I know I top-kicked this little puppy, and may see red for a while, but this is destined to be a 1 year hold, common fill me>>
90% there,,,,,,yes!!filled, now i can go back to sleep and see you in one year,
This company is in the hands of a lawyer petitioning to do a reverse merger, the past officers are long gone and the company is silent and not in production of anything but air.
Taking a position here will pay off with an outstanding of 5.3 million however it will take 9 months to a year to become fully operational again, and we do not know who the new owners are if any.
If the lawyer is just adding this company to his asset bank it could be years before a buyer is found (worst case) or there may be a buyer in the weeds waiting for sec clearance to purchase..
gamble time
Usually it's the old stuckholders that are selling at the first glimmer of hope in their dead investment that holds it down, the entire old ownership may turn over depending on how they trade, and the overall public float.
Production scope .9 million tons per year
evaluation $1.12 B USD
Mine Life 16.73 years
I am looking at $12.00 to $15.00 per share (my valuation) once production is up and running and they plan to be operational within 1 year.
This is obviously an open-pit coal mine in a country that relies on coal
Holdings of Chi Yuan Deng
Equities 2,029,400
% 37.3%
Valuation 629,114 USD
AB International Group Corp. (ABQQ)
(Auto Vehicles, Parts & Service Retailers)
impossible to forward split this share structure, expect to see the authorized get raised ... which if they were smart and can raise money through the markets, that would be the way to go..
early stages here, would like to see more verifiable filings before pulling the trigger, we have time... impatient ones leave the price bottoms out and fill your bill.
outstanding is close to the authorized, so expect a future reverse split or an increase in the authorized, possible low float (not verified) could create some volatility here short term.
calm down, over-hyping only causes bag holders, it's not that great but should be a good runner for a short time before it collapses and the toe rags move on..
At closing the Buyer with have secured the additional working capital
including the funding of the proposed PPE, mask plant
to finance immediate growth activities, including product development and investments in sales and marketing as per attached Schedule
Mr. Abrams specializes in emerging growth companies in several areas, including technology, drug-discovery technology services, consumer products, big data, and online job placement. Mr. Abrams was co-founder of The Software Toolworks, a publicly-held developer, publisher, and distributor of educational and entertainment software, which sold to Pearson, Plc., for $462 million in April 1994. Mr. Abrams also co-founded Intermix Media, the parent company of MySpace, which sold to News Corp, in September 2005 for $580 million. Mr. Abrams is a member of the Board of Trustees at the University of Rochester.
“We are excited to have Joe join our Advisory Board and look forward to working with someone who has a successful track record and understanding of what it takes to grow companies” said William (“Billy”) Robinson, CEO of SEGN.
yes but many investment firms that can and do invest in these things go by committee so that no one gets hung out to dry, so that takes a week to ten days to filter through the office system... it's coming.
All this before the paperwork moves across the closing table, rare find indeed. (iMHO)
+275.0000%
Unfortunately we realize that many failed investors still have a message board habit and cannot find and invest in winning stocks and so in order to be heard they criticize without proof.
I am having a great day! And I am in this one to stay!
YEA! looks like TDS just got the issue with the TA straightened out and also note Synergy owns (and still does) shares of CLHI/TDS.
WOW is that really a winning strategy?? not all of us that play with pennies have pennies to play with...
Day Gain+6,162.40
Someone with deep pockets just bought in. mind you major discount to market but it puts $350k into the treasury and will be restricted for 6 months.. I am lovin it
SECTION 3 - SECURITIES AND TRADING MARKETS
Item 3.02 Unregistered Sales of Equity Securities
On July 30, 2020, we issued a total of 10,000,000 shares of stock to investors at a price of $0.035 per share for proceeds of $350,000.
thanks for the cheap entertainment lol
AIMH research notes, from my original search of the company at the beginning of July.
AIMH
AimRite Holdings Corp.
Market Cap 1,868,240
06/29/2020
Authorized Shares 150,000,000
06/04/2020
Outstanding Share 133,445,698
06/04/2020
Float 6,833,382 06/30/2018
Adam Sexton was a CEO/Director of a company WealthCraft Capital. A company focused on pain management treatment through cannabinoids. A guy named Robert Wilson was President/Director there as well. Robert Wilson is CFO at Nutritional High. Robert Wilson has a 35 year career in fund management and corporate finance.
Another guy that was Chairman at WealthCraft Capital was John MacPhail. John MacPhail was CEO of I-5 Holdings, a subsidiary of Captor Capital. Captor Capital and MedMen have a strategic partnership going back to early 2018.
yes because he knows how to research, and buys and follows through... you have not seen anything yet, if this is not a ten bagger very soon I would be very surprised
original Shark Tank investor Kevin Harrington, has joined its Advisory Board.
no that is a fly by night news promoter company, you can find more official stuff here
https://www.otcmarkets.com/stock/SEGN/disclosure
read and understand every 8-K filing, those are material event notices by public companies... just in case someone does not know
WHOA: I said I bought in two days ago at .25, my hold time is one year.
the daily gain is from my entire account and the + 4% gain is the entire penny port.
This conversation is over, if you are going to build barriers you will never learn.
good luck with your investment decisions.
Sorry, you and I live in two different worlds. My way of trading penny stocks is focused on research, telephone calls, and personal contacts.
MY METHOD OF TRADING WORKS FOR ME... GO FIND YOUR OWN METHOD.
The toe rags got on this stock, they are gone, now true value comes to the stock through the company achievements, no more pom poms at sunrise.